J&J recalls Procrit lot with cracked vials
This article was originally published in Scrip
Johnson & Johnson's Ortho Biotech division has recalled one manufacturing lot of its erythropoiesis-stimulating agent Procrit (epoetin-alfa) in the US owing to cracks in the necks of some vials. More than 44,000 vials in the affected lot were distributed between April 15th and July 17th. The company said it had not received any reports of adverse events or complaints, but cracked vials may lose their sterility and should not be used for subcutaneous or intravenous injection. The amount of Procrit being withdrawn represents a very small proportion of the total product in the distribution channel and J&J does not anticipate a supply disruption.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.